Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells

Life Sciences

Volumn 84, Issue 25-26, 2009, Pages 882-887

  Li, Yuan ^a   Chen, He Qun ^a   Chen, Min Feng ^a   Liu, Huai Zheng ^a   Dai, Yuan Qing ^a   Lv, Hui ^b   Bing Zu, Xiong ^a   Qi, Lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chemotherapy; Neuroendocrine differentiation; Prostate cancer

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; NEURON SPECIFIC ENOLASE;

ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG RESISTANCE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEUROSECRETORY CELL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEUROENDOCRINE CELLS; PHOSPHOPYRUVATE HYDRATASE; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 67349214378     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.03.021     Document Type: Article

References (27)

1. Antonyak M.A., Miller A.M., Jansen J.M., Boehm J.E., Balkman C.E., Wakshlag J.J., Page R.L., and Cerione R.A. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. The Journal of Biological Chemistry 279 40 (2004) 41461-41467
2. Bonkhoff H., Stein U., and Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Human Pathology 26 2 (1995) 167-170
3. Chauhan S.S., Liang X.J., Su A.W., Pai-Panandiker A., Shen D.W., Hanover J.A., and Gottesman M.M. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. British Journal of Cancer 88 8 (2003) 1327-1334
4. Cindolo L., Cantile M., Vacherot F., Terry S., and de La Taille A. Neuroendocrine differentiation in prostate cancer: From lab to bedside. Urologia Internationalis 79 4 (2007) 287-296
5. Di Lorenzo G., Tortora G., D Armiento F.P., De Rosa G., Staibano S., Autorino R., D Armiento M., De Laurentiis M., De Placido S., Catalano G., Bianco A.R., and Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 8 11 (2002) 3438-3444
6. Diss J.K., Faulkes D.J., Walker M.M., Patel A., Foster C.S., Budhram-Mahadeo V., Djamgoz M.B., and Latchman D.S. Brn-3a neuronal transcription factor functional expression in human prostate cancer. Prostate Cancer and Prostatic Diseases 9 1 (2006) 83-91
7. El Sheikh S.S., Domin J., Abel P., Stamp G., and Lalani e.-N. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 6 6 (2004) 846-853
8. Fanidi A., Harrington E.A., and Evan G.I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359 6395 (1992) 554-556
9. Fink D., Aebi S., and Howell S.B. The role of DNA mismatch repair in drug resistance. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 4 1 (1998) 1-6
10. Glynne-Jones E., Goddard L., and Harper M.E. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Human Pathology 27 7 (1996) 688-694
11. Humez S., Monet M., Legrand G., Lepage G., Delcourt P., and Prevarskaya N. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocrine-Related Cancer 13 1 (2006) 181-195
12. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25 4 (2001) 402-408
13. Moriyama-Gonda N., Shiina H., Terashima M., Satoh K., and Igawa M. Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: Primary evidence based on methylation analysis of oestrogen receptor-alpha. BJU International 101 4 (2008) 485-491
14. Moul J.W. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. European Urology 35 5-6 (1999) 399-407
15. Pinski J., Wang Q., Quek M.L., Cole A., Cooc J., Danenberg K., and Danenberg P.V. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 66 11 (2006) 1136-1143
16. Ren A., Yan G., You B., and Sun J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Research 68 7 (2008) 2266-2274
17. Sainz R.M., Mayo J.C., Tan D.X., León J., Manchester L., and Reiter R.J. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63 1 (2005) 29-43
18. Sciarra A., and Salciccia S. New treatment strategies in the management of hormone refractory prostate cancer (HRPC): Only chemotherapy?. European Urology 52 4 (2007) 945-947
19. Shen D.W., Goldenberg S., Pastan I., and Gottesman M.M. Decreased accumulation of (14C)carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. Journal of Cellular Physiology 183 1 (2000) 108-116
20. Tørring N., Jørgensen P.E., Sørensen B.S., and Nexø E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Research 20 1A (2000) 91-95
21. Un F. G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers. Anti-cancer Drugs 18 4 (2007) 411-417
22. Uysal-Onganer P., and Djamgoz M.B. Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: Involvement of voltage-gated sodium channel. Molecular Cancer 6 (2007) 76
23. van Brussel J.P., van Steenbrugge G.J., Romijn J.C., Schröder F.H., and Mickisch G.H. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. European Journal of Cancer 35 4 (1999) 664-671
24. Vashchenko N., and Abrahamsson P.A. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. European Urology 47 2 (2005) 147-155
25. Xing N., Qian J., Bostwick D., Bergstralh E., and Youn C.Y. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48 1 (2001) 7-15
26. Xue Y., Verhofstad A., Lange W., Smedts F., Debruyne F., de La Rosette J., and Schalken J. Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: Cell kinetic features of neuroendocrine cells in the human prostate. The American Journal of Pathology 151 6 (1997) 1759-1765
27. Zalcberg J., Hu X.F., Slater A., Parisot J., El-Osta S., Kantharidis P., Chou S.T., and Parkin J.D. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer and Prostatic Diseases 3 2 (2000) 66-75